Candidiasis – Pipeline Review, H2 2019

Global Markets Direct’s, ‘Candidiasis – Pipeline Review, H2 2019’, provides an overview of the Candidiasis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Candidiasis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Candidiasis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Candidiasis

– The report reviews pipeline therapeutics for Candidiasis by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Candidiasis therapeutics and enlists all their major and minor projects

– The report assesses Candidiasis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Candidiasis

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Candidiasis

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Candidiasis pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Amplyx Pharmaceuticals Inc

APEIRON Biologics AG

Bakker Medical Srl

Beta Pharma Inc

Biosergen AS

Cellix Bio Pvt Ltd

Cidara Therapeutics Inc

Fox Chase Chemical Diversity Center Inc

General Biologicals Corp

Helix BioMedix Inc

iCo Therapeutics Inc

iNtRON Biotechnology Inc

Matinas BioPharma Holdings Inc

Nanomerics Ltd

Next Science Ltd

Nosopharm SAS

Novabiotics Ltd

Novartis AG

Pulmocide Ltd

Scynexis Inc

Sealife PHARMA GMBH

Visterra Inc

Wellstat Vaccines LLC

Table of Contents

Table of Contents

Introduction

Candidiasis ”“ Overview

Candidiasis ”“ Therapeutics Development

Candidiasis ”“ Therapeutics Assessment

Candidiasis ”“ Companies Involved in Therapeutics Development

Candidiasis ”“ Drug Profiles

Candidiasis ”“ Dormant Projects

Candidiasis ”“ Discontinued Products

Candidiasis ”“ Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Candidiasis, H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Number of Products under Development by Universities/Institutes, H2 2019

Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Products under Development by Companies, H2 2019 (Contd..2), H2 2019

Products under Development by Universities/Institutes, H2 2019

Number of Products by Stage and Target, H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Candidiasis ”“ Pipeline by Amplyx Pharmaceuticals Inc, H2 2019

Candidiasis ”“ Pipeline by APEIRON Biologics AG, H2 2019

Candidiasis ”“ Pipeline by Bakker Medical Srl, H2 2019

Candidiasis ”“ Pipeline by Beta Pharma Inc, H2 2019

Candidiasis ”“ Pipeline by Biosergen AS, H2 2019

Candidiasis ”“ Pipeline by Cellix Bio Pvt Ltd, H2 2019

Candidiasis ”“ Pipeline by Cidara Therapeutics Inc, H2 2019

Candidiasis ”“ Pipeline by Fox Chase Chemical Diversity Center Inc, H2 2019

Candidiasis ”“ Pipeline by General Biologicals Corp, H2 2019

Candidiasis ”“ Pipeline by Helix BioMedix Inc, H2 2019

Candidiasis ”“ Pipeline by iCo Therapeutics Inc, H2 2019

Candidiasis ”“ Pipeline by iNtRON Biotechnology Inc, H2 2019

Candidiasis ”“ Pipeline by Matinas BioPharma Holdings Inc, H2 2019

Candidiasis ”“ Pipeline by Nanomerics Ltd, H2 2019

Candidiasis ”“ Pipeline by Next Science Ltd, H2 2019

Candidiasis ”“ Pipeline by Nosopharm SAS, H2 2019

Candidiasis ”“ Pipeline by Novabiotics Ltd, H2 2019

Candidiasis ”“ Pipeline by Novartis AG, H2 2019

Candidiasis ”“ Pipeline by Pulmocide Ltd, H2 2019

Candidiasis ”“ Pipeline by Scynexis Inc, H2 2019

Candidiasis ”“ Pipeline by Sealife PHARMA GMBH, H2 2019

Candidiasis ”“ Pipeline by Visterra Inc, H2 2019

Candidiasis ”“ Pipeline by Wellstat Vaccines LLC, H2 2019

Candidiasis ”“ Dormant Projects, H2 2019

Candidiasis ”“ Dormant Projects, H2 2019 (Contd..1), H2 2019

Candidiasis ”“ Dormant Projects, H2 2019 (Contd..2), H2 2019

Candidiasis ”“ Discontinued Products, H2 2019

List of Figures

List of Figures

Number of Products under Development for Candidiasis, H2 2019 13

Number of Products under Development by Companies, H2 2019 14

Number of Products under Development by Universities/Institutes, H2 2019 17

Number of Products by Top 10 Targets, H2 2019 23

Number of Products by Stage and Top 10 Targets, H2 2019 23

Number of Products by Top 10 Mechanism of Actions, H2 2019 25

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019 25

Number of Products by Top 10 Routes of Administration, H2 2019 27

Number of Products by Stage and Top 10 Routes of Administration, H2 2019 27

Number of Products by Top 10 Molecule Types, H2 2019 29

Number of Products by Stage and Top 10 Molecule Types, H2 2019 29

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports